Matinas Biopharma (NYSEAMERICAN:MTNB) Releases Quarterly Earnings Results

Matinas Biopharma (NYSEAMERICAN:MTNB) posted its quarterly earnings data on Thursday. The company reported ($0.21) EPS for the quarter, FiscalAI reports.

Matinas Biopharma Price Performance

NYSEAMERICAN MTNB traded up $0.00 on Friday, hitting $0.23. The stock had a trading volume of 2,402,845 shares, compared to its average volume of 14,997,717. The business’s fifty day moving average price is $0.49 and its 200 day moving average price is $0.57. Matinas Biopharma has a 52-week low of $0.22 and a 52-week high of $3.09. The stock has a market cap of $1.50 million, a price-to-earnings ratio of -0.20 and a beta of 1.76.

Institutional Trading of Matinas Biopharma

An institutional investor recently bought a new stake in Matinas Biopharma stock. DRW Securities LLC acquired a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned approximately 0.72% of Matinas Biopharma at the end of the most recent reporting period. Institutional investors and hedge funds own 11.77% of the company’s stock.

About Matinas Biopharma

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.